PMID- 36329448
OWN - NLM
STAT- MEDLINE
DCOM- 20221107
LR  - 20221108
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 20
IP  - 1
DP  - 2022 Nov 4
TI  - HIF-1alpha and Caspase-3 expression in aggressive papillary thyroid carcinoma.
PG  - 353
LID - 10.1186/s12957-022-02815-8 [doi]
LID - 353
AB  - BACKGROUND: Tumor cells adapt to hypoxia by regulating transcription factors that 
      involved in regulation of metabolism, angiogenesis, cell proliferation, and 
      apoptosis. Under hypoxic conditions, hypoxia-inducible factor-1 (HIF-1), 
      consisting of HIF-1alpha and HIF-1beta subunits, acts as a key transcription factor 
      mediating the adaptive cellular responses. Caspase-3 is a key apoptosis-related 
      protease that plays a role in tumor growth and development. Studies have shown 
      that caspase-3 could be regulated by HIF-1alpha under pathological conditions. 
      Therefore, HIF-1alpha and caspase-3 expression may be related to the poor prognosis 
      of tumors. In this study, we analyzed the possible relationships between these 
      two signaling factors in correlation with the clinical behavior of PTC. METHODS: 
      We detected the expression levels of HIF-1alpha and caspase-3 in 70 samples of PTC 
      and para-cancerous tissues (control group) by immunohistochemistry (IHC). 
      Furthermore, various clinicopathological parameters were assessed to determine 
      their correlations with HIF-1alpha and caspase-3 expressions. RESULTS: First, HIF-1alpha 
      and caspase-3 expressions (60% and 37.1%, respectively) increased significantly 
      in the PTC samples as compared to normal tissues (2.9% for both HIF-1alpha and 
      caspase-3) (p < 0.05) as determined by IHC. Second, although there was no 
      significant difference between the expression of HIF-1alpha and caspase-3 in regard 
      to gender, age distribution, tumor size, lymph node metastasis, and BRAF(V600E) 
      mutation (all p > 0.05), HIF-1alpha and caspase-3 expressions were associated with 
      capsule invasion and cell subtypes of PTC (p < 0.05). The percent positivity of 
      caspase-3 expression in tall-cell variant (TCV) was the highest (63.6%). Third, 
      HIF-1alpha expression was positively correlated with that of caspase-3 (r(s) = 0.326; 
      p < 0.05). CONCLUSIONS: Overexpression of HIF-1alpha and caspase-3 is associated with 
      carcinogenesis. These factors might serve as promising predictors of aggressive 
      PTC. These findings also suggest their potential as therapeutic targets.
CI  - (c) 2022. The Author(s).
FAU - Zhang, Lili
AU  - Zhang L
AD  - Department of Ultrasound, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Shi, Baixue
AU  - Shi B
AD  - Department of Ultrasound, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Hu, Mingyang
AU  - Hu M
AD  - Department of Ultrasound, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Qian, Linxue
AU  - Qian L
AD  - Department of Ultrasound, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China. qianlinxue2002@163.com.
LA  - eng
PT  - Journal Article
DEP - 20221104
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
RN  - EC 3.4.22.- (Caspase 3)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
SB  - IM
MH  - Humans
MH  - Thyroid Cancer, Papillary
MH  - Caspase 3
MH  - Immunohistochemistry
MH  - *Hypoxia-Inducible Factor 1, alpha Subunit
MH  - *Thyroid Neoplasms/pathology
MH  - Hypoxia
PMC - PMC9635136
OTO - NOTNLM
OT  - Caspase-3
OT  - HIF-1alpha
OT  - Thyroid carcinoma
COIS- The authors declare that they have no competing interests.
EDAT- 2022/11/05 06:00
MHDA- 2022/11/08 06:00
PMCR- 2022/11/04
CRDT- 2022/11/04 00:49
PHST- 2022/05/01 00:00 [received]
PHST- 2022/10/16 00:00 [accepted]
PHST- 2022/11/04 00:49 [entrez]
PHST- 2022/11/05 06:00 [pubmed]
PHST- 2022/11/08 06:00 [medline]
PHST- 2022/11/04 00:00 [pmc-release]
AID - 10.1186/s12957-022-02815-8 [pii]
AID - 2815 [pii]
AID - 10.1186/s12957-022-02815-8 [doi]
PST - epublish
SO  - World J Surg Oncol. 2022 Nov 4;20(1):353. doi: 10.1186/s12957-022-02815-8.